Exploring treatment strategies for HER2-low breast cancer using antibody-drug conjugates

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study retrospectively analyzes clinical data from patients with HER2-low breast cancer who have been treated with sequential antibody-drug conjugates (ADCs). It focuses on evaluating patient demographics, tumor characteristics, treatment regimens, survival outcomes, and safety profiles. The study also integrates genomic data to investigate resistance mechanisms and identify potential prognostic biomarkers. By examining the efficacy of different ADC sequencing approaches, the research aims to provide insights into optimal treatment strategies for this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with HER2-low breast cancer, defined as immunohistochemistry (IHC) score of 1+ or IHC score of 2+ with negative in situ hybridization (FISH-negative)
* Received sequential administration of two or more ADCs
* Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available.

Exclusion Criteria:

* Concomitant with other tumor components at the time of diagnosis;
* Have a history of any other malignant tumors;
* Lack of complete data

Where it's running

• Sun yat-sen University Cancer
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Yang Yalan, Bachelor
• Email: yangylan7@mail2.sysu.edu.cn
• Phone: +8613826282096

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors

  This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.

  Recruiting Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Murcia, Murcia · NCT07917117

• Breast cancer subtypes and outcomes in Colombian women

  This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.

  Recruiting Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. · NCT07856225

• Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making

  This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.

  Recruiting at 3 sites First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin and 2 other locations · NCT07763587

• Slow Jogging for Breast Cancer Survivors

  This study tests whether a 12-week slow jogging program helps sleep quality in women who have completed breast cancer treatment.

  Recruiting Mackay Memorial Hospital · Taipei, Taipei City · NCT07757763

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.